Key result
Oral minoxidil carries uncommon cardiovascular risks with no consistent excess vs comparators except topical formulations.
Why the study?
This study was conducted to evaluate the cardiovascular safety of oral minoxidil in patients with hair loss.
Does oral minoxidil increase the risk of cardiovascular adverse events compared to comparator treatments in patients with hair loss?
Meta-Analysis (n=1,646,680)
Does oral minoxidil increase the risk of cardiovascular adverse events compared to comparator treatments in patients with hair loss?
In a large meta-analysis of over 1.6 million hair-loss patients, oral minoxidil had a generally reassuring cardiovascular safety profile with uncommon adverse events, though it carried higher risk than topical minoxidil and greater symptom susceptibility in women.
Answers are grounded in this paper and cite their sources.
Supports cautious oral minoxidil use for hair loss with monitoring in women; extends meta-analytic evidence of low cardiovascular risk versus most comparators.
This systematic review and meta-analysis evaluated the cardiovascular safety of oral minoxidil (OM) in patients with hair loss by synthesizing evidence from 63 studies involving 1,646,680 participants. Overall, cardiovascular adverse events associated with OM were uncommon, and OM was not consistently associated with increased cardiovascular risk versus any comparator group, although risk was higher relative to topical minoxidil. Female patients additionally demonstrated greater susceptibility to cardiovascular symptoms, however further research is necessary to inform individualized monitoring and prescribing.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) conducted a meta-analysis in Hair loss (n=1,646,680). Oral minoxidil vs. Any comparator group, including topical minoxidil was evaluated on Cardiovascular adverse events / cardiovascular safety. Oral minoxidil in 1,646,680 hair-loss patients across 63 studies showed uncommon cardiovascular adverse events and no consistent increased risk vs comparators, though risk exceeded topical minoxidil.
Synapse has enriched 10 related papers. Consider them for comparative context: